Clinical Trial News and Research

RSS

Beneficial effects of pneumococcal conjugate vaccines in children re-emphasized

Routine infant immunization with pneumococcal conjugate vaccine (PCV7) has caused a 39 percent fall in all-cause pneumonia hospital admission rates for American children under 2, according to an article published in this week's edition of The Lancet .

7 Apr 2007

Alteon expands agreement with Biorap Technologies

Alteon has announced that it has entered into an expanded licensing agreement with BioRap Technologies, the commercialization arm of the Rappaport Family Institute for Research, Technion University, Israel, for all diagnostic devices or products for predictive purposes in vascular or cardiac diseases, including diagnostic assays for the measurement of the haptoglobin protein (Hp).

7 Apr 2007

Lower doses of dexamethasone for multiple myeloma recommended

The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said physicians should consider lowering the dose of the steroid dexamethasone when treating patients with multiple myeloma.

5 Apr 2007

Multiple myeloma trial has shows significant improvement in survival

Mayo Clinic Cancer Center has announced that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone.

5 Apr 2007

No apparent increase in coronary heart disease for women who initiate hormone therapy

Wyeth Pharmaceuticals, a division of Wyeth ( NYSE:WYE ) , provides comment on a re- analysis of pooled data from both hormone therapy arms of the Women's Health Initiative (WHI) Study published today in the Journal of the American Medical Association.

4 Apr 2007

Treatment options for endometriosis

Jan Ruma's pain was getting worse, but she wrote it off as just a part of growing older and a normal side-effect of "that time of the month."

4 Apr 2007

TGF-beta found to be a major player in causing bronchopulmonary dysplasia

Researchers from Massachusetts General Hospital, in collaboration with scientists from the Genzyme Corporation, have identified a potential treatment for a chronic lung disease affecting premature infants.

4 Apr 2007

Genelabs Tech reaches agreement with FDA on special protocol assessment for phase III trial of Prestara in lupus

Genelabs Technologies has announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase III clinical trial of Prestara (prasterone) for treatment of systemic lupus erythematosus (lupus).

4 Apr 2007

Boston Scientific announces enrollment in MAPS clinical trial

The MAPS trial (Matrix And Platinum Science) is designed to identify and investigate clinically relevant endpoints for evaluating the efficacy and durability of endovascular treatment of brain aneurysms.

4 Apr 2007

CSL Biotherapies submits Biologics License Application to FDA

Pending approval of that application, CSL Biotherapies will introduce its influenza vaccine to the U.S. marketplace. The company's BLA requests that the vaccine be approved to immunize people 18 years of age and older.

3 Apr 2007

Philadelphia Inquirer examines efficacy of genetic testing to determine risk of breast cancer relapse

The Philadelphia Inquirer on Sunday examined the efficacy of Genomic Health's Oncotype DX test and Amsterdam, Netherlands-based Agendia's MammaPrint, both of which measure a woman's odds of breast cancer relapse by testing her removed tumor for genes that can predict the likelihood of her cancer returning.

3 Apr 2007

Debate continues over access to experimental medications for terminally ill

USA Today on Monday examined the debate over whether patients with terminal illnesses should have expanded access to experimental medications -- an issue currently under consideration in a lawsuit before the U.S. Court of Appeals for the District of Columbia.

3 Apr 2007

Long-term safety of drug-eluting stents in off-label use

Research presented at the American College of Cardiology's Innovation in Intervention: i2 Summit 2007 in New Orleans, La, paints a picture of the "real world" use of drug-eluting stents and offers new insight into the connection between blood clotting, or thrombosis, in the stent - a dangerous complication - and adherence and responsiveness to anti-clotting medication.

3 Apr 2007

Where you live might play a bigger role in your risk for heart disease than your ethnicity or race

New research reveals that rural residents were more knowledgeable about healthy eating and heart disease risk than urban residents, but that urban residents were more motivated and optimistic about getting healthy.

3 Apr 2007

$Drug that mimics HDL does not reduce risk of death for heart attack patients with refractory shock$

Drug that mimics HDL does not reduce risk of death for heart attack patients with refractory shock

Patients with acute coronary syndromes (ACS), such as heart attack and recent-onset chest pain, remain at considerable risk of experiencing further serious cardiovascular problems despite improvements in care.

2 Apr 2007

Clinical trial of Ranibizumab for edema of the mAcula in diabetes

The Juvenile Diabetes Research Foundation, the world's largest charitable funder of type 1 diabetes research, announced that the Ranibizumab for Edema of the mAcula in Diabetes Phase 2 Study (READ 2) is now enrolling patients.

2 Apr 2007

Adding estradiol to a polymer-free rapamycin-eluting stent is not associated with any measurable benefit

Patients admitted to the hospital with acute coronary syndromes (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention (PCI), during which a stent is inserted into an occluded or narrowed coronary artery to restore blood flow to and from the heart.

2 Apr 2007